Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.54 |
| ▸ | DPP4 | P27487 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374665 | 1.00 | OPRD1 (0.64) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL2373717 | 1.00 | OPRD1 (0.64) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL2374668 | 1.00 | OPRD1 (0.64) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL2373722 | 1.00 | OPRD1 (0.64) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL2373715 | 1.00 | OPRD1 (0.64) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL2374558 | 0.92 | OPRD1 (0.69) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL2374566 | 0.92 | OPRD1 (0.69) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL6052747 | 0.82 | HDAC8 (0.59) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL4095232 | 0.82 | HDAC8 (0.59) | OPRD1HDAC8DPP4POLBDPP8 | |
| SCHEMBL4086820 | 0.82 | HDAC8 (0.59) | OPRD1HDAC8DPP4POLBDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | OPRD1 3687/4885HDAC8 16/4885DPP4 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.